OSL — Oncosil Medical Income Statement
0.000.00%
Last trade - 00:00
- AU$46.65m
- AU$42.22m
- AU$0.39m
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.87 | 1.38 | 1.07 | 0.43 | 0.387 |
Cost of Revenue | |||||
Gross Profit | — | 0.42 | 0.101 | -1.16 | -0.995 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7.12 | 11.7 | 11.6 | 11.7 | 12.5 |
Operating Profit | -4.25 | -10.3 | -10.6 | -11.3 | -12.1 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -4.26 | -10.4 | -10.7 | -11.3 | -12.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.26 | -10.4 | -10.7 | -11.3 | -12.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.26 | -10.4 | -10.7 | -11.3 | -12.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.26 | -10.4 | -10.7 | -11.3 | -12.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.005 | -0.01 | -0.01 | -0.009 | -0.006 |